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Introduction: Therapeutic mammaplasty (TM) may be an alternative to mastectomy but few well-
designed studies have evaluated the success of this approach or compared the short-term outcomes 
of TM with mastectomy with or without (+/-) immediate breast reconstruction (IBR).  Data from the 
national iBRA-2 and TeaM studies were combined to compare the safety and short-term outcomes of 
TM and mastectomy +/- IBR 
Method: The subgroup of patients in the TeaM study who underwent TM to avoid mastectomy were 
identified and demographic, complication, oncology, and adjuvant treatment data compared to patients 
undergoing mastectomy +/- IBR in the iBRA-2 study.  The primary outcome was the percentage of 
successful breast conserving surgery (BCS) in the TM group.  Secondary outcomes included post-
operative complications and time to adjuvant therapy.  
Results: 2,916 patients; (TM n=376; mastectomy n=1532; IBR n=1008; [implant-based n=675; 
pedicled-flap n=105; free-flap n=228]) were included in the analysis.  Patients undergoing TM were 
more likely to be obese and to have undergone bilateral surgery than those undergoing IBR. However, 
patients undergoing mastectomy +/- IBR were more likely to experience complications than the TM 
group (TM n=79, 21.0%; mastectomy n=570, 37.2%; mastectomy and IBR n=359, 35.6%; p<0.001).  
Breast conservation was possible in 87% of TM patients. TM did not delay adjuvant treatment.     
Conclusion: TM may allow high-risk patients who would not be candidates for IBR to safely avoid 
mastectomy.  Further work is needed to explore the comparative patient-reported and cosmetic 
outcomes of the different approaches and to establish long-term oncological safety. 
 











Breast conserving surgery (BCS) and adjuvant radiotherapy is the preferred option for many women 
with breast cancer1.  However, standard BCS often results in poor cosmetic outcomes which can 
adversely impact women’s quality of life2-6. Volume of tissue resected, in particular, is a predictor of 
poor outcome7 8. Mastectomy is therefore often recommended for patients with large or multiple 
tumours and currently 40%9 of the 55,000 women10 diagnosed with breast cancer every year undergo 
this form of treatment in the UK.  Although national guidelines11 recommend that immediate breast 
reconstruction (IBR) should be routinely offered in this group, only a quarter of women undergoing 
mastectomy currently receive immediate reconstruction12 13.  Many thousands of women therefore 
have a simple mastectomy which can dramatically impact their psychological well-being14 15.  
Therapeutic mammaplasty (TM) is a procedure that combines a wide local excision to remove the 
cancer with breast reduction and mastopexy techniques to reshape the remaining tissue16 17.  These 
techniques can extend the boundaries of BCS by allowing adequate resection of large or multifocal 
cancers in patients with medium/large or ptotic breasts without compromising oncological outcomes18-
20.  This may offer women a safe and effective alternative to mastectomy, with or without 
reconstruction.   
There is however, limited high-quality comparative evidence to support the benefits of TM as an 
alternative to mastectomy with or without IBR.  Single-centre case-series suggest that overall, patients 
undergoing TM may report better quality of life than those undergoing mastectomy and IBR21 22 and 
there is emerging evidence to suggest that TM may be a cost-effective alternative to mastectomy and 
immediate implant-based23 and free-flap reconstruction24 in a North American setting.  
While these results are promising, there remains a need for high-quality research to establish the 
benefits of TM as a safe and effective alternative to mastectomy with or without IBR25.  Randomised 
controlled trials (RCTs) are ideally needed but RCTs in this context are not feasible due to patient and 
surgeon preference26-28.  A large-scale multicentre prospective cohort study is therefore required to 
compare the clinical and patient-reported outcomes of TM and mastectomy and to establish the cost-
effectiveness of the approach.  Before such a study can be planned, however, preliminary work is 
needed to explore what proportion of patients could potentially avoid mastectomy by undergoing a TM 
procedure and the relative safety of this approach.  Two large trainee-led prospective cohort studies 




have evaluated the short-term outcomes of TM29 and mastectomy with and without IBR30 separately.  
In the current study, we undertook a pooled analysis to evaluate the potential for TM to successfully 
avoid mastectomy and compare the short-term outcomes of the different techniques.  
Methods  
The methods for the iBRA-230 31 and TeaM29 32 prospective cohort studies have been reported 
previously.  Both studies collected identical data items during an overlapping time period and 37 
centres participated in both studies supporting the validity of a pooled analysis. 
In brief, all breast and plastic surgical units performing mastectomy with and without IBR and TM were 
invited to participate in the iBRA-2 and TeaM studies respectively via the professional associations 
(Association of Breast Surgery [ABS] and British Association of Plastic Reconstructive and Aesthetic 
Surgeons [BAPRAS] and the breast and plastic surgery collaborative research networks 
(Reconstructive Surgery Trials Network [RSTN] and the Mammary Fold Academic and Research 
Collaborative [MFAC]).   
Consecutive patients undergoing mastectomy with or without IBR for invasive or pre-invasive breast 
cancer between July and December 2016 at participating centres were recruited prospectively to the 
iBRA-2 study. 
Patients undergoing TM defined as ‘the oncoplastic application of breast reduction or mastopexy 
techniques including removal of skin to reduce the skin envelope to treat invasive or pre-invasive 
(ductal carcinoma in situ; DCIS) breast cancer using breast conserving surgery’32 between 1st 
September 2016 and 30th June 2017 at participating centres were recruited to the TeaM study.  
Surgeon-reported indication for offering TM was recorded prospectively and only the subgroup of 
patients offered TM ‘to avoid mastectomy’ were included in the current study.    
Patients in both studies were identified from multidisciplinary team (MDT) meetings; operating diaries 
and clinics.  Demographic and operative data were collected prospectively and oncological data 
including adequacy of resection for TM patients and recommended adjuvant treatments were obtained 
from post-operative MDT meetings.  Date of first adjuvant treatment was obtained by review of 
appropriate clinical information systems. Complications, readmissions and re-operations were 




collected prospectively by clinical or case-note review depending on whether the patient needed to 
attend for follow up. REDCap33 data capture software was used for data collection in both studies.  
Both studies were classified as service evaluations according to the NHS Health Research Authority 
online decision tool http://www.hra-decisiontools.org.uk/research/ so ethical approval was not 
required. Each participating centre was required to register the study locally and obtain local 
governance approvals prior to entering patients in the studies. 
Primary and secondary outcomes 
Primary and secondary outcomes in iBRA-2 and TeaM were selected based on current best practice34 
and the National Institute of Health and Care Excellence (NICE) guidelines11.  Standardised definitions 
were used across both studies allowing for meaningful pooling of the data29 30.   
The primary outcome for this study was the percentage of patients successfully avoiding mastectomy 
in the TM group.  Secondary outcomes were major and minor complications and time to adjuvant 
therapy.  Major complications were defined as complications requiring readmission or re-operation and 
minor complications were those that were managed conservatively.  Time to adjuvant treatment was 
defined as time from last cancer surgery to first dose of chemotherapy or first fraction of radiotherapy. 
Adequate margins were defined in the TeaM study according to local policy29 32.   
Quality assurance 
For quality assurance purposes, the lead investigator at each site was asked to identify an individual 
not previously involved in data collection to independently validate 5-10% of the data.  Similar 
procedures were used in both studies and are consistent with those used in other collaborative 
projects35. 
Statistical analysis 
Data from patients undergoing mastectomy with and without IBR in the iBRA-2 study and the 
subgroup of patients undergoing TM to avoid mastectomy in the TeaM study were combined to 
compare the short-term clinical and oncological outcomes of the different procedure types.   
Descriptive summary statistics were calculated for each variable for the pooled cohort overall and split 
by procedure type (therapeutic mammaplasty; mastectomy only; mastectomy and immediate breast 




reconstruction).  Categorical data were summarised by counts and percentages and continuous data 
by median, interquartile range (IQR), and range.  Procedure groups were compared using Chi-
squared and Kruskall-Wallis tests.  Complications and oncological data were summarised by patient 
and procedure.    
Univariable and multivariable logistic regression were used to explore clinicopathological variables 
hypothesised to be associated with complications based on the literature and expert opinion.  These 
included patient and procedure-related factors namely age, body mass index (BMI), smoking status, 
American Society of Anaesthesiologists’ (ASA) grade; diabetes, ischaemic heart disease (IHD); other 
comorbidities, neoadjuvant chemotherapy (NAC), unilateral vs bilateral surgery to the breast, axillary 
surgery (none; sentinel node biopsy [SNB]; axillary node clearance [ANC]), and procedure type 
(therapeutic mammaplasty; mastectomy only; mastectomy and immediate breast reconstruction).   
Time to adjuvant treatment was calculated for all patients and by procedure type with adjuvant therapy 
as the event.  Kaplan-Meier analyses, univariable and multivariable Cox survival models with time to 
adjuvant therapy split by procedure type were created including patient age; BMI, diabetes, IHD, other 
co-morbidities, smoking status (non-smoker; ex-smoker and current smoker); neoadjuvant 
chemotherapy, ASA grade and unilateral vs. bilateral surgery and presence of post-operative 
complications (none, minor and major) as the variables of interest, clustered by centre.  The Kaplan 
Meier curves were curtailed at 150 days when only 14 patients remained in the analysis.   
STATA 15 (STATA Inc, Texas) was used for all analyses. 
Results 
The TeaM study29 recruited 376  patients undergoing 385 TM procedures to avoid mastectomy from 
50 centres in the UK and Europe between 1st September 2016 and 30th June 2017.  
The iBRA-2 study30 recruited 2,540 patients undergoing mastectomy with (n=1008) and without 
(n=1564) IBR from 76 centres between 1st July and 31st December 2016.  Of the 1008 patients 
receiving IBR, 675 patients underwent 773 implant-based reconstructions; 105 patients received 106 
pedicled-flaps and 228 patients underwent 247 free-flap reconstructions.  Data from these cohorts 
were pooled and 2,916 patients were included in the combined analysis. 
 





Table 1 summarises patient demographics by procedure type.  Patients undergoing TM were older 
than patients undergoing IBR.  They also had higher BMIs and were more likely to have undergone 
simultaneous bilateral surgery than patients in the other groups (table 1).  Participant demographics by 
type of reconstruction performed are summarised in supplementary table 1. 
Post-operative complications 
Post-operative complications by procedure type are summarised in table 2 with details of 
complications by type of IBR and per breast summarised in supplementary tables 2 and 3 
respectively.  Complications following TM were significantly lower than those observed following 
mastectomy with or without immediate reconstruction. Only 1 in 5 (n=79, 21.0%) patients undergoing 
TM experienced a complication compared with approximately a third of patients undergoing 
mastectomy with (n=359, 35.6%) or without (n=570, 37.2%) IBR (table 2). Univariable regression 
identified age, BMI, diabetes, IHD, having other co-morbidities, being an ex-smoker, ASA grade, and 
undergoing an ANC as risk factors associated with developing a complication.  Compared to 
undergoing a simple mastectomy without reconstruction, TM was associated with a reduced risk of 
complications (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.31-0.63) but immediate 
reconstruction did not increase the risk (table 3).  Age, BMI, other co-morbidities being an ex-smoker 
and undergoing an ANC remained strongly associated with complications in the multivariable model 
and current smoking and bilateral surgery were also identified as independent risk factors.  
Undergoing a TM remained strongly associated with a lower risk of complications (adjusted odd ratio 
[aOR] 0.46, 95% CI 0.30-0.71) in the multivariable model (table 3).  
Major complications following TM were uncommon with just 2% (n=8) of patients requiring 
readmission or reoperation for a complication of their surgery.  This compares with 5% (n=76) of 
patients undergoing mastectomy only and 14% (n=145) of patients receiving immediate reconstruction 
(table 2).  Age, undergoing immediate reconstruction and bilateral surgery were associated with major 
complications in the univariable analysis (table 3).  All of these variables, except age, remained 
strongly associated with major complications in the multivariable model and smoking, diabetes, having 
other co-morbidities and BMI were also identified as independent risk factors in this model.  Immediate 
breast reconstruction (aOR 4.02, 95% CI 2.23-7.25) was the strongest predictor of major 




complications in the multivariable model with undergoing TM associated with a lower risk of 
experiencing a major complication in both univariable (OR 0.41, 95% CI 0.20-0.84) and multivariable 
models (aOR 0.36, 95% CI 0.15-0.85) (table 3).    Univariable and multivariable analysis of risk factors 
for any and major complications by type of reconstruction performed are summarised in 
supplementary table 4. 
Oncological outcomes  
Table 4 summarises post-operative histology by the procedure performed.  TM was performed less 
frequently for pure DCIS than mastectomy with immediate reconstruction. Approximately a third of all 
patients (n=956, 32.0%) had multifocal disease, including those who had TM (n=120, 31.2%).  The 
median invasive and whole tumour size (WTS) were similar in in the TM and immediate reconstruction 
groups.  Patients undergoing IBR were more likely to be node negative than patients in the other 
groups (table 4). 
The 376 patients in the TeaM study underwent 385 TM procedures for cancer.  Of these, 305 (79.2%) 
had clear margins according to local guidelines at the first operation; 71 (18.4%) had involved or close 
margins and the margin status was unknown in 9 (2.3%) cases.  In the group for whom margins were 
not adequate, 30/71 (42.3%) had a successful re-excision; 33 (46.5%) underwent completion 
mastectomy.  The outcome of the remaining 8 (11.3%) cases was unknown.  Overall, 335/385 (87.0%) 
TM procedures resulted in successful breast conservation.  Notably, of the 33/71 (46.5%) who 
required a completion mastectomy, only 11 (32.3%) had an IBR within the study period (figure 1).    
Time to adjuvant therapy 
Adjuvant therapy was recommended in the majority of patients in the TM group (n=343, 91.2%) 
compared with less than half (n=431, 42.8%) in those undergoing immediate reconstruction (table 5).  
There was no significant difference in the median time to adjuvant treatment across the treatment 
groups (table 5). Longer time to adjuvant treatment was associated with the development of 
complications (minor complications, aHR 0.85, 95% CI 0.74-0.97; major complications aHR 0.63, 95% 
CI 0.51-0.78) and obesity (aHR 0.75, 95% CI 0.64-0.88) in this analysis (table 6).   Further details of 
time to adjuvant treatment and risk factors for delays to adjuvant treatment by type of IBR are 
summarised in supplementary tables 5 and 6 respectively. 





This large prospective study suggests that TM may allow the majority of women considered suitable 
for the procedure to successfully avoid mastectomy and that overall, TM is associated with fewer 
complications than mastectomy and immediate reconstruction.  TM may particularly improve 
outcomes for patients considered high-risk (current smokers, high BMI) who may not be offered 
immediate reconstruction because of their risk profile. Reducing risk of complications with breast 
cancer surgery is an important consideration as complications have been shown to result in delays to 
adjuvant therapy30 which could adversely impact on long-term oncological outcomes and compromise 
survival.   
The rate of successful breast conservation in this subset of patients offered TM to avoid mastectomy 
was higher than may be expected based on previous systematic reviews that demonstrate higher 
completion mastectomy rates in patients with smaller (T1) tumours36-38.  The patients in the current 
study had larger tumours, validating the inclusion criteria that the TM group were offered this option as 
an alternative to mastectomy.  Despite this, the completion mastectomy rate in the current study was 
less than 10%.  This is consistent with previous findings39 and suggests that TM is a viable option for 
allowing women to avoid mastectomy.  Recent retrospective data from a large population-based study 
suggests that oncoplastic breast conservation may occupy a niche between standard BCS and 
mastectomy40.  Our study suggests that it should possibly be promoted as an alternative to 
mastectomy and reconstruction. 
Currently, the recommendation for mastectomy is clearly defined for those with extensive disease. 
Likewise, the role of breast conservation is clear for those with relatively small disease foci who can be 
anticipated to achieve an acceptable cosmetic outcome. There is, however, a widening middle ground 
in which the extended role of breast conservation offered by oncoplastic surgery can provide an 
alternative to mastectomy.  Patients suitable for TM will have breast ptosis and be accepting of being 
smaller breasted and, usually, undergoing bilateral surgery. The extended role of breast conservation 
has been fuelled by neoadjuvant therapy, better understanding of tumour biology, and increasingly 
widespread oncoplastic surgical training with the result that surgeons with an understanding of 
reduction and mastopexy techniques are more likely to routinely consider and offer these options41. 




Good cosmetic outcomes are reported42 and there is emerging data to suggest that avoiding 
mastectomy and IBR may be associated with improvements in quality of life21.   
At the limits of the spectrum the term ‘extreme oncoplasty’21 has even emerged to describe resections 
of large tumours (T3), multifocal or multicentric disease that would traditionally have been 
recommended mastectomy43.  Single-centre series are generally small but mostly show promising 
results with low rates of conversion to mastectomy although long-term oncological outcomes are 
lacking42-44.   
The rate of IBR in patients requiring completion mastectomy following unsuccessful TM in the current 
study is low.  This may be because they were considered high-risk and therefore not good candidates 
for IBR but may also reflect the anticipated need for post-mastectomy radiotherapy. Evidence 
suggesting oncological benefits of postmastectomy radiotherapy in patients with one to three positive 
lymph nodes45 means that many more patients are now offered treatment.   Radiotherapy has been 
shown to adversely impact both clinical and patient-reported outcomes of immediate breast 
reconstruction46, particularly with implants47 and despite recent updated national guidance48, many 
surgeons would not offer immediate reconstruction if postmastectomy radiotherapy is likely to be 
required13.  Avoiding mastectomy may therefore have particular benefits in this group but work is 
needed to explore this further.   
This study adds to the evidence-base to support the benefits of TM compared to mastectomy but has 
limitations.  Firstly, this is a pooled analysis of two separate studies, and it is not clear to what extent 
these groups are directly comparable.  In particular, although the overall post-operative tumour size 
and proportion of patients with multifocality in both groups was similar, we did not assess how many 
patients in the iBRA-2 cohort would be technically suitable for TM for morphological (e.g. small, non-
ptotic breasts) or tumour related (e.g. multicentric disease) reasons or the proportion who would elect 
to undergo TM to avoid mastectomy. A future prospective study in patients offered all surgical options 
will therefore be needed to directly compare the outcomes of different operative procedure types and 
explore patient decision-making.  Only short-term outcomes of TM such as complications and time to 
adjuvant therapy have been considered in this study.  While these data are promising, further long-
term studies will be needed to prospectively assess the oncological safety, particularly of more 
extreme oncoplastic resections as well as the patient-reported and cosmetic outcomes and cost-




effectiveness of as TM compared to mastectomy with and without immediate reconstruction in directly 
comparable patient groups.     
A future study directly comparing TM as an alternative to mastectomy with and without IBR in patients 
with large, multifocal and/or multicentre tumours is the next step in generating the evidence needed to 
change practice and improve outcomes for patients.  Recent experience with the MIAMI feasibility 
study49 (ISRCTN17987569) has demonstrated that an RCT in this context is unlikely to be feasible. A 
well-designed multicentre prospective study including validated patient-reported outcomes and a cost-
effectiveness analysis is needed but preliminary work will be required to determine whether it is 
possible to identify and recruit patients to all treatment groups if fully informed choice is offered and to 
establish the optimal study design.  A key issue is the selection of an appropriate patient-reported 
outcome assessment tool.  The BREAST-Q50 includes core breast cancer modules with four 
subscales (satisfaction with breasts, psychosocial well-being; physical well-being and sexual well-
being) for use in patients with breast cancer having BCS and mastectomy with and without immediate 
reconstruction.  These scales are comparable but to date, only one study has used the BCS 
‘satisfaction with breasts’ scale in patients undergoing TM procedures51.  Work is therefore needed to 
determine whether it is valid in this group.  Qualitative work is also needed to explore patients’ 
decision making for, and experiences of, different types of surgery and factors influencing their choice. 
This will provide important information to help inform shared decision-making consultations in the main 
study and allow patients to make the choice that is right for them.   
This study shows that oncoplastic breast conservation is likely to offer better outcomes than 
mastectomy with or without breast reconstruction for many women, and together with emerging 
evidence to support the long-term oncological safety18 20 52 of oncoplastic breast conservation adds 
further support to the use of therapeutic mammaplasty as an alternative to mastectomy.  Further work 
is now needed determine whether TM improves patient-reported outcomes and is cost-effective 
compared to mastectomy with and without immediate breast reconstruction before definitive 
recommendations for best practice can be made. 
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Table 1: Demographics of participants by procedure type 












Age in years, median 
(IQR) (range) 
57 (48-68) (21-96) 56 (49-65) (29-85) 65 (54-75) (26-96) 50 (44-57) (21-82) <0.001k 
<35 100 (3.4%) 11 (2.9%) 34 (2.2%) 55 (5.5%) <0.001χ 
35-44 370 (12.7%) 33 (8.8%) 115 (7.5%) 222 (22.0%)  
45-54 769 (26.4%) 114 (30.3%) 257 (16.8%) 398 (39.5%)  
55-64 659 (22.6%) 122 (32.5%) 320 (20.9%) 217 (21.5%)  
65-75 580 (19.9%) 71 (18.9%) 406 (26.5%) 103 (10.2%)  
>75 425 (14.6%) 23 (6.1%) 392 (25.6%) 10 (1.0%)  
Not reported 13 (0.5%) 2 (0.5%) 8 (0.5%) 3 (0.3%)  














Underweight  56 (1.9%) 1 (0.3%) 33 (2.2%) 22 (2.2%) <0.001χ 
Normal  967 (33.2%) 87 (23.1%) 445 (29.0%) 435 (43.2%)  
Overweight 883 (30.3%) 114 (30.3%) 457 (29.8%) 312 (31.0%)  
Obese  477 (16.4%) 97 (25.8%) 252 (16.4%) 128 (12.7%)  
Severely obese  346 (11.9%) 69 (18.4%) 221 (14.4%) 56 (5.6%)  
Not reported 187 (6.4%) 8 (2.1%) 124 (8.1%) 55 (5.5%)  
Smoking status     
0.516χ 
Non-smoker 2097 (71.9%) 278 (73.9%) 1082 (70.6%) 737 (73.1%) 
Current smoker 316 (10.8%) 40 (10.6%) 180 (11.7%) 96 (9.5%) 
Ex-smoker 452 (15.5%) 51 (13.6%) 241 (15.7%) 160 (15.9%) 
Missing  51 (1.8%) 7 (1.9%) 29 (1.9%) 15 (1.5%) 
Co-morbidities      
Diabetes 248 (8.5%) 16 (4.3%) 189 (12.3%) 43 (4.3%) <0.001χ 
Ischaemic heart 
disease 
151 (5.2%) 11 (2.9%) 133 (8.7%) 7 (0.7%) <0.001χ 
Other co-morbidity 1329 (45.6%) 143 (38.0%) 848 (55.3%) 338 (33.5%) <0.001χ 
Previous oncological 
therapy 
     
Neoadjuvant 
chemotherapy 
478 (16.4%) 56 (14.9%) 230 (15.0%) 192 (19.1%) 0.034χ 
Neoadjuvant endocrine 
therapy 
210 (7.2%) 24 (6.4%) 136 (8.9%) 50 (5.0%) <0.001χ 
ASA grade     
<0.001χ 
Grade 1 840 (28.8%) 135 (35.9%) 333 (21.7%) 372 (36.9%) 
Grade 2 1729 (59.3%) 223 (59.3%) 906 (59.1%) 600 (59.5%) 
Grade 3 329 (11.3%) 16 (4.3%) 279 (18.2%) 34 (3.4%) 
Grade 4  6 (0.2%) 0 (0.0%) 6 (0.4%) 0 (0.0%) 
Missing 12 (0.4%) 2 (0.5%) 8 (0.5%) 2 (0.2%) 
Laterality of surgery      
<0.001χ 
Unilateral TM/Mx+/-IBR 2476 (84.9%) 241 (64.1%) 1427 (93.2%) 808 (80.2%) 




217 (7.4%) 126 (33.5%) 19 (1.2%) 72 (7.1%) 
Unilateral TM/Mx+/-IBR 
+ contralateral 
oncological procedure  
36 (0.9%) 1 (0.3%) 15 (1.0%) 10 (1.0%) 
Axillary surgery*     
<0.001χ 
None 192 (6.6%) 65 (17.3%) 49 (3.2%) 78 (7.7%) 
Sentinel node 
biopsy/Axillary sample 
1674 (57.4%) 251 (66.8%) 871 (56.9%) 552 (54.8%) 
Axillary clearance 759 (26.0%) 60 (16.0%) 506 (33.0%) 193 (19.2%) 
Missing 291 (10.0%) 0 (0.0%) 106 (6.9%) 185 (18.4%)  
kKruskal-Wallis test across procedure groups, xChi-squared test across procedure groups; ASA – American Society of 
Anaesthesiologists; BMI – body mass index; IBR – immediate breast reconstruction; IQR – interquartile range; Mx – mastectomy; 
SNB – sentinel node biopsy; TM – therapeutic mammoplasty *axillary surgery performed at the time of therapeutic 
mammaplasty/mastectomy +/- IBR based on pre-operative assessment of disease (e.g. axillary surgery not routinely performed 





Therapeutic mammaplasty is an effective alternative to mastectomy 
 
 
Table 2: Post-operative complications by patient 













At least one breast or donor 
site complication 
1008 (34.6%) 79 (21.0%) 570 (37.2%) 359 (35.6%) <0.001a 
Any major complication  229 (7.9%) 8 (2.1%) 76 (5.0%) 145 (14.4%) <0.001a 
Unplanned readmission 
following surgery 
188 (6.5%) 4 (1.1%) 60 (3.9%) 124 (12.3%) <0.001a 
Re-operation for 
complications of surgery 
133 (4.6%) 8 (2.1%) 29 (1.9%) 96 (9.5%) <0.001a 
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Any complication Major complications 
Univariable Multivariable (n=2313) Univariable Multivariable (n=2289) 
N (events, %) Odds ratio  
(95% Confidence intervals) 
p value Odds ratio  
(95% confidence intervals) 
p value N (events, %) Odds ratio (95% 
Confidence intervals) 
p value Odds ratio (95% 
confidence intervals) 
p value 
Procedure type 2893 (1008, 34.8%)     2868 (229, 8.0%)     
Therapeutic mammaplasty 376 (79, 21.0%) 0.44 (0.31, 0.63) <0.001 0.46 (0.30, 0.71) <0.001 376 (8, 2.1%) 0.41 (0.20, 0.84) 0.014 0.36 (0.15, 0.85) 0.019 
Mastectomy only 1517 (570, 37.6%) Reference  Reference  1499 (76, 5.1%) Reference  Reference  
Mastectomy and immediate breast reconstruction 1000 (359, 35.9%) 0.93 (0.74, 1.17) 0.535 1.28 (0.95, 1.72) 0.109 993 (145, 14.6%) 3.20 (2.20, 4.65) <0.001 4.02 (2.23, 7.25) <0.001 
Age 2880 (1005, 34.9%) 1.01 (1.01, 1.02) <0.001 1.01 (1.01, 1.02) 0.002 2855 (229, 8.0%) 0.99 (0.98, 1.00) 0.022 1.01 (0.99, 1.03) 0.172 
BMI 2707 (947, 35.0%)     2682 (216, 8.1%)     
Underweight 55 (16, 29.1%) 1.04 (0.56, 1.93) 0.911 0.85 (0.53, 1.37) 0.497 53 (4, 7.6%) 0.95 (0.27, 3.41) 0.939 1.55 (0.57, 4.25) 0.395 
Normal weight 959 (272, 28.4%) Reference  Reference  949 (75, 7.9%) Reference  Reference  
Overweight 874 (315, 36.0%) 1.42 (1.15, 1.77) 0.001 1.27 (0.98, 1.65) 0.076 869 (58, 6.7%) 0.83 (0.58, 1.19) 0.315 0.95 (0.64, 1.41) 0.794 
Obese 476 (199, 41.8%) 1.81 (1.44, 2.29) <0.001 1.77 (1.33, 2.34) <0.001 470 (48, 10.2%) 1.33 (0.92, 1.90) 0.125 1.65 (1.05, 2.59) 0.030 
Severely obese 343 (145, 42.3%) 1.85 (1.37, 2.50) <0.001 1.74 (1.17, 2.58) 0.006 341 (31, 9.1%) 1.17 (0.75, 1.82) 0.501 1.67 (0.92, 3.03) 0.093 
Co-morbidities           
Ischaemic heart disease 2868 (1001, 34.9%)     2844 (228, 8.0%)     
No 2719 (937, 34.5%) Reference  Reference  2695 (220, 8.2%) Reference  Reference  
Yes 149 (64, 43.0%) 1.43 (1.00, 2.04) 0.048 1.06 (0.70, 1.61) 0.785 149 (8, 5.4%) 0.64 (0.34, 1.20) 0.163 0.69 (0.27, 1.72) 0.424 
Diabetes 2829 (986, 34.9%)     2804 (224, 8.0%)     
No 2583 (874, 33.8%) Reference  Reference  2558 (198, 7.7%) Reference  Reference  
Yes 246 (112, 45.5%) 1.63 (1.27, 2.11) <0.001 1.09 (0.79, 1.50) 0.598 246 (26, 10.6%) 1.41 (0.91, 2.17) 0.120 1.66 (1.04, 2.64) 0.035 
Other 2874 (1003, 34.9%)     2849 (228, 8.0%)     
No 1550 (468, 30.2%) Reference  Reference  1540 (111, 7.2%) Reference  Reference  
Yes 1324 (535, 40.4%) 1.57 (1.29, 1.90) <0.001 1.32 (1.04, 1.66) 0.022 1309 (117, 8.9%) 1.26 (0.97, 1.65) 0.082 1.43 (1.03, 2.00) 0.035 
Smoking status 2843 (993, 34.9%)     2818 (228, 8.1%)     
Non-smoker 2078 (689, 33.2%) Reference  Reference  2060 (154, 7.5%) Reference  Reference  
Ex-smoker 450 (184, 40.9%) 1.39 (1.13, 1.72) 0.002 1.29 (1.02, 1.63) 0.031 446 (41, 9.2%) 1.25 (0.86, 1.82) 0.236 1.16 (0.77, 1.74) 0.482 
Current smoker 315 (120, 38.1%) 1.24 (0.99, 1.56) 0.066 1.43 (1.11, 1.83) 0.005 312 (33, 10.6%) 1.46 (0.96, 2.24) 0.079 1.84 (1.17, 2.89) 0.008 
Neoadjuvant chemotherapy 2872 (1002, 34.9%)     2848 (228, 8.0%)     
No 475 (153, 32.2%) Reference  Reference  470 (42, 8.9%) Reference  Reference  
Yes 2397 (849, 35.4%) 0.87 (0.68, 1.11) 0.254 0.82 (0.61, 1.10) 0.179 2378 (186, 7.8%) 1.16 (0.75, 1.78) 0.510 1.24 (0.76, 2.02) 0.399 
ASA grade 2881 (1005, 34.9%)     2856 (228, 8.0%)     
1 837 (238, 28.4%) Reference  Reference  835 (63, 7.5%) Reference  Reference  
2 1710 (624, 36.5%) 1.45 (1.20, 1.74) <0.001 1.07 (0.83, 1.37) 0.600 1687 (141, 8.4%) 1.12 (0.83, 1.50) 0.463 0.87 (0.61, 1.23) 0.428 
3 328 (140, 42.7%) 1.87 (1.44, 2.45) <0.001 1.03 (0.70, 1.54) 0.867 328 (24, 7.3%) 0.97 (0.59, 1.59) 0.896 0.88 (0.47, 1.65) 0.689 
4 6 (3, 50.0%) 2.52 (0.50, 12.72) 0.264 0.96 (0.16, 5.80) 0.962 6 (0, 0.0%) NA NA NA NA 
Bilateral surgery 2893 (1008, 34.8%)     2868 (229, 8.0%)     
No 2455 (843, 34.3%) Reference  Reference  2433 (181, 7.4%) Reference  Reference  
Yes 438 (165, 37.7%) 1.16 (0.88, 1.52) 0.301 1.54 (1.18, 2.01) 0.001 435 (48, 11.0%) 1.54 (1.07, 2.23) 0.021 1.71 (1.14, 2.57) 0.010 
Axillary surgery 2604 (909, 34.9%)     2582 (196, 7.6%)     
None 192 (26.6%) Reference  Reference  188 (11, 5.9%) Reference  Reference  
Sentinel node biopsy/Axillary sample 1661 (548, 33.0%) 1.36 (0.91, 2.03) 0.130 1.13 (0.74, 1.71) 0.480 1650 (134, 8.1%) 1.42 (0.83, 2.44) 0.201 1.33 (0.77, 2.27) 0.304 
Axillary clearance 751 (310, 41.3%) 1.94 (1.26, 3.01) 0.003 1.69 (1.04, 2.74) 0.033 744 (51, 6.9%) 1.18 (0.65, 2.15) 0.578 1.08 (0.59, 1.97) 0.801 
ASA – American Society of Anaesthesiologists, BMI – body mass index, NA – Not applicable 




Table 4: Postoperative histology in procedures performed for malignancy 













Invasive status     
<0.001x 
DCIS 406 (13.6%) 18 (4.7%) 141 (9.0%) 247 (23.7%) 
Invasive disease 2547 (85.1%) 361 (93.8%) 1413 (90.4%) 773 (74.1%) 
Not reported 39 (1.3%) 6 (1.6%) 10 (0.6%) 23 (2.2%) 
Focality     
0.002x 
Unifocal disease 1998 (66.8%) 258 (67.0%) 1091 (69.8%) 649 (62.2%) 
Multifocal disease 956 (32.0%) 120 (31.2%) 455 (29.1%) 381 (36.5%) 
Not reported 38 (1.3%) 7 (1.8%) 18 (1.2%) 13 (1.3%) 
Invasive disease (n=2547) (n=361) (n=1413) (n=773) 
<0.001x 
Grade      
Grade 1 223 (8.8%) 44 (12.2%) 98 (6.9%) 81 (10.5%) 
Grade 2 1327 (52.1%) 140 (38.8%) 759 (53.7%) 428 (55.4%) 
Grade 3 920 (36.1%) 120 (33.2%) 543 (38.4%) 257 (33.3%) 
Not reported 77 (3.0%) 57 (15.8%) 13 (0.9%) 7 (0.9%) 
Histological type      
0.078x 
Ductal  1783 (70.0%) 243 (67.3%) 986 (69.8%) 554 (71.7%) 
Lobular 426 (16.7%) 53 (14.7%) 246 (17.4%) 127 (16.4%) 
Mixed/Other 326 (12.8%) 64 (17.7%) 175 (12.4%) 87 (11.3%) 
Not reported 12 (0.5%) 1 (0.3%) 6 (0.4%) 5 (0.7%) 
Invasive tumour size 
(mm) median (IQR) 
(range) 
23 (13-36)  
(0-250) 







Whole tumour size 
(mm) median (IQR) 
(range) 




32 (20-50)  
(0-450) 
30 (17-50)  
(0-250) 
0.003k 
Receptor status*       
ER      
<0.001x 
Positive 2017 (79.2%) 279 (77.3%) 1106 (78.3%) 632 (81.8%) 
Negative 484 (19.0%) 51 (14.1%) 298 (21.1%) 135 (17.5%) 
Unknown 46 (1.8%) 31 (8.6%) 9 (0.6%) 6 (0.8%) 
HER-2     
<0.001x 
Positive 478 (18.8%) 56 (15.5%) 273 (19.3%) 149 (19.3%) 
Negative 1947 (76.4%) 261 (72.3%) 1087 (76.9%) 599 (77.5%) 
Unknown 122 (4.8%) 44 (12.2%) 53 (3.8%) 25 (3.2%) 
Nodal status      
Number of lymph nodes 
involved (macromets 
only) median (IQR) 
(range) 
0 (0-1)  
(0-31) 




0 (0-1) (0-31) <0.001k 
N0 1888 (63.1%) 225 (58.4%) 905 (57.9%) 758 (72.7%) <0.001x 
N1 984 (32.9%) 87 (22.6%) 642 (41.1%) 255 (24.5%)  
Not reported 120 (4.0%) 73 (19.0%) 17 (1.1%) 30 (2.9%)  
DCIS (n=406) (n=18) (n=141) (n=247) 
0.613x 
Low grade 27 (6.7%) 13 (72.2%) 7 (5.0%) 20 (8.1%) 
Intermediate grade 95 (23.4%) 5 (27.8%) 38 (27.0%) 52 (21.1%) 
High grade 282 (69.5%) 0 (0.0%) 95 (67.4%) 174 (70.5%) 
Not reported 2 (0.5%) 0 (0.0%) 1 (0.7%) 1 (0.4%) 
*Invasive disease only; kKruskal-Wallis test across procedure groups, xChi-squared test across procedure groups 














Table 5: Multidisciplinary team decision-making and time to adjuvant therapy by 
procedure type 
 


















1578 (54.1%) 343 (91.2%) 804 (52.8%) 431 (42.8%) <0.001x 
Time from last 
oncological 
procedure to first 
adjuvant treatment 
(days) median (IQR) 
(n=1432) 




719 (50.2%) 92 (30.6%) 409 (55.4%) 218 (55.5%) <0.001x 




(days) median (IQR) 
(n=719) 
47 (37-59) 49 (41-60) 47 (37-59) 47 (37-60) 0.592k 
Radiotherapy as 1st 
adjuvant treatment 
713 (49.8%) 209 (69.4%) 329 (44.6%) 175 (44.5%) <0.001x 






59 (48-72) 57 (48-70) 59 (48-73) 61 (47-73) 0.632k 
IQR – interquartile range; MDT – multidisciplinary team;  













Table 6: Cox univariable and multivariable survival analyses for adjuvant treatment 
   Univariable  Multivariable (N=1301)  
  N (%) Hazard Ratio (95% 
Confidence Intervals) 




Procedure type 1432     
Therapeutic Mammaplasty 301 (21.0%) 0.89 (0.77, 1.02) 0.102 1.06 (0.87, 1.29) 0.548 
Mastectomy only 738 (51.5%) Reference  Reference  
Mastectomy and immediate breast 
reconstruction 
393 (27.4%) 0.97 (0.85, 1.10) 0.600 0.96 (0.82, 1.12) 0.571 
Post-operative complications 1432     
None 861 (60.1%) Reference  Reference  
Minor complications 478 (33.4%) 0.83 (0.74, 0.93) 0.002 0.85 (0.74, 0.97) 0.017 
Major complications 93 (6.5%) 0.71 (0.58, 0.87) 0.001 0.63 (0.51, 0.78) <0.001 
Chemotherapy as first adjuvant 
treatment 
719 (50.2%) 1.71 (1.50, 1.94) <0.001 2.11 (1.84, 2.41) <0.001 
Age 1428 1.00 (0.99, 1.00) 0.202 1.01 (1.00, 1.01) 0.043 
BMI 1373     
Underweight 29 (2.1%) 0.83 (0.64, 1.07) 0.152 0.88 (0.63, 1.22) 0.429 
Normal weight 453 (33.0%) Reference  Reference  
Overweight 447 (32.6%) 0.97 (0.85, 1.12) 0.701 0.97 (0.84, 1.13) 0.726 
Obese 266 (19.4%) 0.73 (0.64, 0.83) <0.001 0.75 (0.64, 0.88) <0.001 
Severely obese 178 (13.0%) 0.73 (0.62, 0.86) <0.001 0.79 (0.65, 0.95) 0.015 
Co-morbidities      
Ischaemic heart disease 1428     
No 1372 (96.1%) Reference  Reference  
Yes 56 (3.9%) 0.69 (0.55, 0.86) <0.001 0.78 (0.59, 1.05) 0.100 
Diabetes 1403     
No 1290 (92.0%) Reference  Reference  
Yes 113 (8.1%) 0.82 (0.72, 0.94) 0.005 0.97 (0.82, 1.14) 0.718 
Other comorbidity 1422     
No 824 (58.0%) Reference  Reference  
Yes 598 (42.1%) 0.91 (0.80, 1.03) 0.151 0.90 (0.75, 1.09) 0.285 
Smoking status 1409     
Non-smoker 1031 (73.2%) Reference  Reference  
Ex-smoker 204 (14.5%) 1.14 (0.98, 1.33) 0.089 1.18 (1.00, 1.40) 0.038 
Current smoker 174 (12.4%) 0.93 (0.81, 1.07) 0.315 0.92 (0.79, 1.08) 0.326 
Neoadjuvant chemotherapy 1421     
No 1083 (76.2%) Reference  Reference  
Yes 338 (23.8%) 1.03 (0.92, 1.15) 0.603 1.56 (1.33, 1.82) <0.001 
ASA grade 1425     
1 474 (33.3%) Reference  Reference  
2 823 (57.8%) 0.92 (0.81, 1.03) 0.133 1.04 (0.88, 1.21) 0.657 
3 126 (8.8%) 0.86 (0.70, 1.05) 0.144 1.05 (0.78, 1.43) 0.731 
4 2 (0.1%) 0.75 (0.63, 0.89) 0.001 1.29 (0.94, 1.78) 0.119 
Bilateral surgery (vs none) 232 (16.2%) 1.01 (0.86, 1.17) 0.927 1.03 (0.84, 1.26) 0.797 
ASA – American Society of Anaesthesiologists, BMI – body mass index 
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<35 100 (3.4%) 11 (2.9%) 34 (2.2%) 42 (6.2%) 4 (3.8%) 9 (4.0%) <0.001χ 
35-44 370 (12.7%) 33 (8.8%) 115 (7.5%) 160 (23.7%) 14 (13.3%) 48 (21.1%)  
45-54 769 (26.4%) 114 (30.3%) 257 (16.8%) 248 (36.7%) 50 (47.6%) 100 (43.9%)  
55-64 659 (22.6%) 122 (32.5%) 320 (20.9%) 141 (20.9%) 22 (21.0%) 54 (23.7%)  
65-75 580 (19.9%) 71 (18.9%) 406 (26.5%) 71 (10.5%) 15 (14.3%) 17 (7.5%)  
>75 425 (14.6%) 23 (6.1%) 392 (25.6%) 10 (1.5%) 0 (0.0%) 0 (0.0%)  
Not reported 13 (0.5%) 2 (0.5%) 8 (0.5%) 3 (0.4%) 0 (0.0%) 0 (0.0%)  



















Underweight  56 (1.9%) 1 (0.3%) 33 (2.2%) 20 (3.0%) 0 (0.0%) 2 (0.9%) <0.001χ 
Normal  967 (33.2%) 87 (23.1%) 445 (29.0%) 328 (48.6%) 37 (35.2%) 70 (30.7%)  
Overweight 883 (30.3%) 114 (30.3%) 457 (29.8%) 191 (28.3%) 35 (33.3%) 86 (37.7%)  
Obese  477 (16.4%) 97 (25.8%) 252 (16.4%) 65 (9.6%) 22 (21.0%) 41 (18. 0%)  
Severely obese  346 (11.9%) 69 (18.4%) 221 (14.4%) 35 (5.2%) 5 (4.8%) 16 (7.0%)  
Not reported 187 (6.4%) 8 (2.1%) 124 (8.1%) 36 (5.3%) 6 (5.7%) 13 (5.7%)  
Smoking status       
0.038χ 
Non-smoker 2097 (71.9%) 278 (73.9%) 1082 (70.6%) 499 (73.9%) 75 (71.4%) 163 (71.5%) 
Current smoker 327 (11.2%) 51 (13.6%) 180 (11.7%) 73 (10.8%) 12 (11.4%) 11 (4.8%) 
Ex-smoker 441 (15.1%) 40 (10.6%) 241 (15.7%) 91 (13.5%) 18 (17.1%) 51 (22.4%) 
Missing  51 (1.8%) 7 (1.9%) 29 (1.9%) 12 (1.8%) 0 (0.0%) 3 (1.3%) 
Co-morbidities        





133 (8.7%) 3 (0.4%) 2 (1.9%) 2 (0.9%) <0.001χ 















136 (8.9%) 28 (4.1%) 8 (7.6%) 14 (6.1%) <0.001χ 
ASA grade       
<0.001χ 
Grade 1 840 (28.8%) 135 (35.9%) 333 (21.7%) 273 (40.4%) 40 (38.1%) 59 (25.9%) 
Grade 2 1729 (59.3%) 223 (59.3%) 906 (59.1%) 379 (56.2%) 61 (58.1%) 160 (70.2%) 
Grade 3 329 (11.3%) 16 (4.3%) 279 (18.2%) 23 (3.4%) 3 (2.9%) 8 (3.5%) 
Grade 4  6 (0.2%) 0 (0.0%) 6 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Missing 12 (0.4%) 2 (0.5%) 8 (0.5%) 0 (0.0%) 1 (1.0%) 1 (0.4%) 















217 (7.4%) 126 (33.5%) 19 (1.2%) 43 (6.4%) 8 (7.6%) 21 (9.2%) 
Unilateral TM/Mx+/-
IBR + contralateral 
oncological 
procedure  
36 (0.9%) 1 (0.3%) 15 (1.0%) 6 (0.9%) 0 (0.0%) 4 (1.8%) 
Axillary surgery       
<0.001χ 




1674 (57.4%) 251 (66.8%) 871 (56.9%) 419 (62.1%) 38 (36.2%) 95 (41.7%) 
Axillary clearance 759 (26.0%) 60 (16.0%) 506 (33.0%) 119 (17.6%) 26 (24.8%) 48 (21.1%) 
Missing 291 (10.0%) 0 (0.0%) 106 (6.9%) 97 (14.4%) 29 (27.6%) 59 (25.9%)  
kKruskal-Wallis test, xChi-squared test; ASA – American Society of Anaesthesiologists; BMI – body mass index; IBR – immediate 



























At least one breast or 
donor site complication 
1008 
(34.6%) 







Any major complication  229 
(7.9%) 
8 (2.1%) 76 (5.0%) 100 
(14.8%) 







4 (1.1%) 60 (3.9%) 88 
(13.0%) 




complications of surgery 
133 
(4.6%) 
8 (2.1%) 29 (1.9%) 69 
(10.2%) 
5 (4.8%) 22 
(9.7%) 
<0.001a 
aChi squared test 
 
 
Supplementary Table 3: Details of complications per breast (n (%)) by procedure type 
 
Complication 













Seroma requiring aspiration 15 (3.9) 434 (27.0) 77 (10.0) 7 (6.6) 10 (4.1) <0.001 
Haematoma 
Managed conservatively 



















Requiring oral antibiotics 
Requiring intravenous therapy antibiotics 























Skin necrosis, including T junction necrosis 
Minor – managed conservatively 






































xChi-squared test across procedure groups 
 
 




Any complication Major complications 
Univariable Multivariable (n=2313) Univariable Multivariable (n=2289) 
N (events, %) Odds ratio  
(95% Confidence intervals) 
p value Odds ratio  
(95% confidence intervals) 
p value N (events, %) Odds ratio (95% 
Confidence intervals) 
p value Odds ratio (95% 
confidence intervals) 
p value 
Procedure type 2893 (1008, 34.8%)     2868 (229, 8.0%)     
Therapeutic mammaplasty 376 (79, 21.0%) 0.44 (0.31, 0.63) <0.001 0.46 (0.30, 0.71) <0.001 376 (8, 2.1%) 0.41 (0.20, 0.84) 0.014 0.37 (0.16, 0.86) 0.021 
Mastectomy only 1517 (570, 37.6%) Reference  Reference  1499 (76, 5.1%) Reference  Reference  
Implant-based 667 (223, 33.4%) 0.83 (0.64, 1.08) 0.170 1.15 (0.83, 1.59) 0.401 663 (100, 15.1%) 3.33 (2.17, 5.09) <0.001 4.28 (2.28, 8.01) <0.001 
Pedicled flap 105 (42, 40.0%) 1.11 (0.61, 2.00) 0.735 1.55 (0.84, 2.87) 0.164 104 (7, 6.7%) 1.35 (0.66, 2.78) 0.414 1.43 (0.52, 3.95) 0.488 
Free flap 228 (94, 41.2%) 1.17 (0.83, 1.64) 0.377 1.62 (0.99, 2.63) 0.053 226 (38, 16.8%) 3.78 (2.38, 6.01) <0.001 4.92 (2.31, 10.48) <0.001 
Age 2880 (1005, 34.9%) 1.01 (1.01, 1.02) <0.001 1.01 (1.01, 1.02) 0.002 2855 (229, 8.0%) 0.99 (0.98, 1.00) 0.022 1.01 (0.99, 1.03) 0.172 
BMI 2707 (947, 35.0%)     2682 (216, 8.1%)     
Underweight 55 (16, 29.1%) 1.04 (0.56, 1.93) 0.911 0.84 (0.52, 1.36) 0.486 53 (4, 7.6%) 0.95 (0.27, 3.41) 0.939 1.53 (0.55, 4.21) 0.415 
Normal weight 959 (272, 28.4%) Reference  Reference  949 (75, 7.9%) Reference  Reference  
Overweight 874 (315, 36.0%) 1.42 (1.15, 1.77) 0.001 1.24 (0.95, 1.62) 0.106 869 (58, 6.7%) 0.83 (0.58, 1.19) 0.315 0.95 (0.63, 1.42) 0.798 
Obese 476 (199, 41.8%) 1.81 (1.44, 2.29) <0.001 1.73 (1.30, 2.29) <0.001 470 (48, 10.2%) 1.33 (0.92, 1.90) 0.125 1.71 (1.08, 2.70) 0.022 
Severely obese 343 (145, 42.3%) 1.85 (1.37, 2.50) <0.001 1.71 (1.15, 2.55) 0.009 341 (31, 9.1%) 1.17 (0.75, 1.82) 0.501 1.70 (0.94, 3.07) 0.079 
Co-morbidities           
Ischaemic heart disease 2868 (1001, 34.9%)     2844 (228, 8.0%)     
No 2719 (937, 34.5%) Reference  Reference  2695 (220, 8.2%) Reference  Reference  
Yes 149 (64, 43.0%) 1.43 (1.00, 2.04) 0.048 1.05 (0.69, 1.60) 0.807 149 (8, 5.4%) 0.64 (0.34, 1.20) 0.163 0.68 (0.27, 1.71) 0.416 
Diabetes 2829 (986, 34.9%)     2804 (224, 8.0%)     
No 2583 (874, 33.8%) Reference  Reference  2558 (198, 7.7%) Reference  Reference  
Yes 246 (112, 45.5%) 1.63 (1.27, 2.11) <0.001 1.09 (0.79, 1.50) 0.593 246 (26, 10.6%) 1.41 (0.91, 2.17) 0.120 1.68 (1.05, 2.68) 0.031 
Other 2874 (1003, 34.9%)     2849 (228, 8.0%)     
No 1550 (468, 30.2%) Reference  Reference  1540 (111, 7.2%) Reference  Reference  
Yes 1324 (535, 40.4%) 1.57 (1.29, 1.90) <0.001 1.32 (1.04, 1.67) 0.023 1309 (117, 8.9%) 1.26 (0.97, 1.65) 0.082 1.43 (1.02, 2.01) 0.038 
Smoking status 2843 (993, 34.9%)     2818 (228, 8.1%)     
Non-smoker 2078 (689, 33.2%) Reference  Reference  2060 (154, 7.5%) Reference  Reference  
Ex-smoker 450 (184, 40.9%) 1.39 (1.13, 1.72) 0.002 1.28 (1.01, 1.61) 0.039 446 (41, 9.2%) 1.25 (0.86, 1.82) 0.236 1.16 (0.78, 1.74) 0.467 
Current smoker 315 (120, 38.1%) 1.24 (0.99, 1.56) 0.066 1.44 (1.13, 1.84) 0.004 312 (33, 10.6%) 1.46 (0.96, 2.24) 0.079 1.88 (1.19, 2.99) 0.007 
Neoadjuvant chemotherapy 2872 (1002, 34.9%)     2848 (228, 8.0%)     
No 475 (153, 32.2%) Reference  Reference  470 (42, 8.9%) Reference  Reference  
Yes 2397 (849, 35.4%) 0.87 (0.68, 1.11) 0.254 0.82 (0.61, 1.10) 0.187 2378 (186, 7.8%) 1.16 (0.75, 1.78) 0.510 1.21 (0.74, 1.98) 0.445 
ASA grade 2881 (1005, 34.9%)     2856 (228, 8.0%)     
1 837 (238, 28.4%) Reference  Reference  835 (63, 7.5%) Reference  Reference  
2 1710 (624, 36.5%) 1.45 (1.20, 1.74) <0.001 1.06 (0.82, 1.36) 0.662 1687 (141, 8.4%) 1.12 (0.83, 1.50) 0.463 0.83 (0.58, 1.20) 0.327 
3 328 (140, 42.7%) 1.87 (1.44, 2.45) <0.001 1.03 (0.69, 1.53) 0.888 328 (24, 7.3%) 0.97 (0.59, 1.59) 0.896 0.84 (0.44, 1.58) 0.584 
4 6 (3, 50.0%) 2.52 (0.50, 12.72) 0.264 0.96 (0.16, 5.80) 0.962 6 (0, 0.0%) NA NA NA NA 
Bilateral surgery 2893 (1008, 34.8%)     2868 (229, 8.0%)     
No 2455 (843, 34.3%) Reference  Reference  2433 (181, 7.4%) Reference  Reference  
Yes 438 (165, 37.7%) 1.16 (0.88, 1.52) 0.301 1.56 (1.19, 2.03) 0.001 435 (48, 11.0%) 1.54 (1.07, 2.23) 0.021 1.65 (1.09, 2.51) 0.018 
Axillary surgery 2604 (909, 34.9%)     2582 (196, 7.6%)     
None 192 (26.6%) Reference  Reference  188 (11, 5.9%) Reference  Reference  
Sentinel node biopsy/Axillary sample 1661 (548, 33.0%) 1.36 (0.91, 2.03) 0.130 1.17 (0.76, 1.79) 0.480 1650 (134, 8.1%) 1.42 (0.83, 2.44) 0.201 1.29 (0.75, 2.21) 0.357 
Axillary clearance 751 (310, 41.3%) 1.94 (1.26, 3.01) 0.003 1.73 (1.05, 2.83) 0.030 744 (51, 6.9%) 1.18 (0.65, 2.15) 0.578 1.08 (0.58, 2.00) 0.817 




Supplementary table 5: Postoperative histology in procedures performed for 
malignancy 















Invasive status       
<0.001 
DCIS 406 (13.6%) 18 (4.7%) 141 (9.0%) 163 (23.1%) 26 (24.8%) 58 (25.1%) 
Invasive disease 2547 (85.1%) 361 (93.8%) 1413 (90.4%) 533 (75.4%) 77 (73.3%) 163 (70.6%) 
Not reported 39 (1.3%) 6 (1.6%) 10 (0.6%) 11 (1.6%) 2 (1.9%) 10 (4.3%) 
Focality       
0.002 
Unifocal disease 1998 (66.8%) 258 (67.0%) 1091 (69.8%) 446 (63.1%) 72 (68.6%) 131 (56.7%) 
Multifocal disease 956 (32.0%) 120 (31.2%) 455 (29.1%) 251 (35.5%) 33 (31.4%) 97 (42.0%) 
Not reported 38 (1.3%) 7 (1.8%) 18 (1.2%) 10 (1.4%) 0 (0.0%) 3 (1.3%) 
Invasive disease (n=2547) (n=361) (n=1413) (n=533) (n=77) (n=163) 
<0.001 
Grade        
Grade 1 223 (8.8%) 44 (12.2%) 98 (6.9%) 58 (10.9%) 7 (9.1%) 16 (9.8%) 
Grade 2 1327 (52.1%) 140 (38.8%) 759 (53.7%) 285 (53.5%) 47 (61.0%) 96 (58.9%) 
Grade 3 920 (36.1%) 120 (33.2%) 543 (38.4%) 186 (24.1%) 21 (27.3%) 50 (30.7%) 
Not reported 77 (3.0%) 57 (15.8%) 13 (0.9%) 4 (0.8%) 2 (2.6%) 1 (0.6%) 
Histological type        
0.081 
Ductal  1783 (70.0%) 243 (67.3%) 986 (69.8%) 382 (71.7%) 55 (71.4%) 117 (71.8%) 
Lobular 426 (16.7%) 53 (14.7%) 246 (17.4%) 89 (16.7%) 10 (13.0%) 28 (17.2%) 
Mixed/Other 326 (12.8%) 64 (17.7%) 175 (12.4%) 60 (11.3%) 10 (13.0%) 17 (10.4%) 
Not reported 12 (0.5%) 1 (0.3%) 6 (0.4%) 2 (0.4%) 2 (2.6%) 1 (0.6%) 
Invasive tumour size 















Whole tumour size 















Receptor status*         
ER        
<0.001 
Positive 2017 (79.2%) 279 (77.3%) 1106 (78.3%) 445 (83.5%) 56 (72.7%) 131 (80.4%) 
Negative 484 (19.0%) 51 (14.1%) 298 (21.1%) 86 (16.1%) 18 (23.4%) 31 (19.0%) 
Unknown 46 (1.8%) 31 (8.6%) 9 (0.6%) 2 (0.4%) 3 (3.9%) 1 (0.6%) 
HER-2       
<0.001 
Positive 478 (18.8%) 56 (15.5%) 273 (19.3%) 109 (20.5%) 12 (15.6%) 28 (17.2%) 
Negative 1947 (76.4%) 261 (72.3%) 1087 (76.9%) 408 (76.6%) 61 (79.2%) 130 (79.8%) 
Unknown 122 (4.8%) 44 (12.2%) 53 (3.8%) 16 (3.0%) 4 (5.2%) 5 (3.1%) 
Nodal status        
Number of lymph 
nodes involved 
(macromets only) 
median (IQR) (range) 










N0 1888 (63.1%) 225 (58.4%) 905 (57.9%) 523 (74.0%) 71 (67.6%) 164 (71.0%) <0.001 
N1 984 (32.9%) 87 (22.6%) 642 (41.1%) 168 (23.8%) 28 (26.7%) 59 (25.5%)  
Not reported 120 (4.0%) 73 (19.0%) 17 (1.1%) 16 (2.3%) 6 (5.7%) 8 (3.5%)  
Preinvasive disease (n=406) (n=18) (n=141) (n=163) (n=26) (n=58) 
0.743 
Low grade 27 (6.7%) 13 (72.2%) 7 (5.0%) 12 (7.4%) 1 (3.8%) 7 (12.1%) 
Intermediate grade 95 (23.4%) 5 (27.8%) 38 (27.0%) 38 (23.3%) 5 (19.2%) 9 (15.5%) 
High grade 282 (69.5%) 0 (0.0%) 95 (67.4%) 112 (68.7%) 20 (76.9%) 42 (72.4%) 
Not reported 2 (0.5%) 0 (0.0%) 1 (0.7%) 1 (0.6%) 0 (0.0%) 0 (0.0%) 








Supplementary table 6: Multidisciplinary team decision-making and time to adjuvant 
therapy by procedure type 
 
























343 (91.2%) 804 (52.8%) 288 (42.7%) 50 (47.6%) 93 (40.8%) <0.001 
Time from last 
oncological procedure 




53 (42-65) 55 (43-67) 52 (41-66) 51 (41-63) 57 (42-73) 57 (46-72) 0.007 
Chemotherapy as 1st 
adjuvant treatment 
719 (50.2%) 92 (30.6%) 409 (55.4%) 147 (56.5%) 25 (52.1%) 46 (54.1%) <0.001 
Time from last 
oncological procedure 
to chemotherapy 
(days) median (IQR) 
(n=719) 
47 (37-59) 49 (41-60) 47 (37-59) 46 (35-57) 46 (39-64) 57 (41-70) 0.087 
Radiotherapy as 1st 
adjuvant treatment 
713 (49.8%) 209 (69.4%) 329 (44.6%) 113 (43.5%) 23 (47.9%) 39 (45.9%) <0.001 
Time from last 
oncological procedure 
to radiotherapy (days) 
median (IQR) (n=713)  
59 (48-72) 57 (48-70) 59 (48-73) 60 (45-68) 63 (53-85) 62 (50-76) 0.292 
IQR – interquartile range; MDT – multidisciplinary team 
 
 
